Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia

Next Previous
Trial Profile

The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms HypoDeg

Most Recent Events

  • 06 Oct 2023 Primary endpoint (Symptomatic nocturnal hypoglycaemia) has been met, as per results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
  • 06 Oct 2023 Results assessing the proportion of participants to whom the overall result is applicable to analyzed data from the HypoDeg trial on hypoglycaemia and HbA1c outcomes at a single-patient level, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
  • 23 Sep 2022 Results (n=149) of substudy comparing treatment with IDeg or IGla in patients with T1D and at least one nocturnal severe hypoglycaemic event within thelast two years presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top